Respiratory failure & ventilation
Anti-C5a Antibody STSA-1002 for Patients With ARDS Due to Viral Pneumonia: A Phase 1b/2, Multicenter, Randomized, Double-Anonymized, Placebo-Controlled Trial
Authors' conclusion
STSA-1002 exhibited a favorable safety profile and potential efficacy.
Study context
- Population
- Adults aged 18–85 y with ARDS caused by viral pneumonia and PaO2/FiO2 ≤ 200 mm Hg47 received study medication
- Participants
- 49 adults
- Comparison
- STSA-1002 1,350 mg or 750 mg vs placebo
- STSA-1002 1,350 mgn = 17
- STSA-1002 750 mgn = 15
- Placebon = 15reference
- Primary endpoint
- Time to clinical improvement (SpO2/FiO2 > 235 mm Hg or PaO2/FiO2 > 200 mm Hg, maintained ≥48 h, whichever first)
- Follow-up
- Within 28 days
Methodological detailsphase 1b/2, multicentre, double-anonymized, placebo-controlled
- Phase 1b/2
- Multicentre
- Double-anonymized
- Placebo-controlled
Primary result
As reported in the abstract
Time to clinical improvement
Each group vs placeboSubdistribution hazard ratio (95% CI)
STSA-1002 1,350 mg
1.55(0.68–3.55)
STSA-1002 750 mg
1.04(0.46–2.38)
Further findings
| Outcome | Subdistribution HR (95% CI) | |
|---|---|---|
| Time to clinical improvement, adjusted for baseline PaO2/FiO2 · 28 daysSTSA-1002 1,350 mg vs Placebo | 1.22 (0.52–2.86) | |
| Time to clinical improvement, adjusted for baseline PaO2/FiO2 · 28 daysSTSA-1002 750 mg vs Placebo | 1.13 (0.47–2.75) | |
| 0.20.5125Subdistribution hazard ratio (log scale) |
Safety
Tolerability
- STSA-1002 was well tolerated
Parts of this Brief are withheld: the automatic checks could not confirm them against the abstract.
Original publication
Anti-C5a Antibody STSA-1002 for Patients With ARDS Due to Viral Pneumonia: A Phase 1b/2, Multicenter, Randomized, Double-Anonymized, Placebo-Controlled Trial. Chest. Published 15 May 2026. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →